Integer Holdings Corporation
ITGRInteger Holdings Corporation (ITGR) is a global medical device manufacturer that designs and produces specialized medical devices and components. The company focuses on critical, life-sustaining products used in various medical specialties such as neuromonitoring, cardiac rhythm management, vascular, and orthopedics. With a history rooted in innovative healthcare solutions, Integer serves medical device OEMs and healthcare providers worldwide.
Company News
Integer Holdings Corporation (NYSE: ITGR), a leading medical device CDMO, announced its participation in the Truist Securities 2026 MedTech Conference on June 16, 2026. Executive leadership will participate in a fireside chat, with live webcast available on the company's investor relations website.
Integer Holdings (ITGR) surged over 5% after Oppenheimer analyst Suraj Kalia upgraded the stock to 'outperform' with a $115 price target. The upgrade was driven by Integer's announcement of a strategic review, suggesting potential acquisition interest from private equity firms. As a contract development and manufacturing organization (CDMO) for m...
The global medical device contract development and manufacturing organization (CDMO) market is expected to expand significantly at a CAGR of 13.12% from 2026 to 2033, driven by increased outsourcing by OEMs, demand for advanced connected devices, and the shift toward home care and minimally invasive treatments. CDMOs are becoming essential partne...
Integer Holdings Corporation announced that independent Board Chair Pamela G. Bailey will not seek re-election at the May 20, 2026 Annual Meeting. Donald J. Spence, a director since 2016 and former CEO of Ebb Therapeutics and Lake Region Medical, will be appointed as the new independent Chair following the meeting.
Integer Holdings Corporation's stock has declined 28% over the past year. VP Corporate Controller Tom Thomas sold 825 shares worth $70,000 on March 13, 2026, representing 15.85% of his direct holdings. The article characterizes this as routine liquidity management rather than a loss of confidence. Despite revenue growth of 8% YoY to $1.85 billion...
